International Clinical Trial: Real-World Study of Icotinib as Adjuvant Therapy for Stage IA2-IA3 EGFR-Positive Non-Small Cell Lung Cancer with High-Risk Factors

Geneva, Jan. 12 -- International Clinical Trials Registry received information related to the study (ChiCTR2500115161) titled 'Real-World Study of Icotinib as Adjuvant Therapy for Stage IA2-IA3 EGFR-Positive Non-Small Cell Lung Cancer with High-Risk Factors' on Dec. 23, 2025.

Study Type: Interventional study

Study Design: Single arm

Primary Sponsor: Beijing Hospital

Condition: Lung cancer

Recruitment Status: Not Recruiting

Phase: N/A

Date of First Enrollment: 2025-12-24

Target Sample Size: Single arm:88;

Countries of Recruitment: China

To know more, visit https://www.chictr.org.cn/showproj.html?proj=300666

Published by HT Digital Content Services with permission from Health Daily Digest....